Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03228017 · ClinicalTrials.gov registry record · Phase 4
Subclinical Cardiovascular Disease in Psoriatic Disease
A Phase 4 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 63
- Enrollment target
NCT03228017 is a Phase 4 study that has completed, run by NYU Langone Health. The registered enrollment target is 63 participants.
The verdict
NCT03228017, a Phase 4 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 63 participants
- Enrollment target
Study Summary
This study will look at how chronic inflammation seen in psoriatic disease translates into the increased atherosclerotic and thrombotic risk and how treatment reduces this CVD risk. The Aim of this study is to 1) Evaluate the association between moderate to severe psoriatic disease and measures of vascular function. 2) Evaluate the association between moderate to severe psoriatic disease and measures of thrombotic risk. 3) Understand how traditional medications used in cardiovascular disease (CVD) prevention such as aspirin and statins affect vascular function and thrombotic risk in those with moderate to severe psoriatic disease.
Interventions
- DRUG Aspirin and/or Atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2019-04-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03228017
The ClinicalTrials.gov registry entry for NCT03228017 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aspirin and/or Atorvastatin is the first listed.
NCT03228017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03228017 about?
NCT03228017 is a clinical study titled "Subclinical Cardiovascular Disease in Psoriatic Disease". This study will look at how chronic inflammation seen in psoriatic disease translates into the increased atherosclerotic and thrombotic risk and how treatment reduces this CVD risk. The Aim of this study is to 1) Evaluate the association between moderate to severe psoriatic disease and measures of v...
What is the current status of trial NCT03228017?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 63 participants. The study started on 2017-08-01. Estimated completion is 2019-04-01.
What interventions are being tested in trial NCT03228017?
The interventions under investigation include: Aspirin and/or Atorvastatin (DRUG).
Who is sponsoring clinical trial NCT03228017?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.